
Speciality Medicines IPO
- Issue price
- ₹124
- Listing price
- ₹124
- 0.00%
- Current price
- ₹169.4
- +36.61%
- Subscribed
- 2.19x
- Issue size
- ₹29 Cr
- Listed on
- 30 Mar 2026
IPO timeline
- Opens20 MarFri
- Closes24 MarTue
- Allotment25 MarWed
- Refunds27 MarFri
- Demat credit27 MarFri
- Listing30 MarMon
Issue details
- Price band
- ₹117 – ₹124 per share
- Issue size
- ₹29 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- NII Shares Offered
- Face value
- ₹10 per share
- Lot size
- 1,000 shares
- Minimum investment
- ₹1,24,000
- Listing on
- BSE SME
- Exchange code
- 544738.BO · 7653
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 1,000 | ₹1,24,000 |
| Retail (Max) | 1 | 1,000 | ₹1,24,000 |
| HNI (Min) | 2 | 2,000 | ₹2,48,000 |
Reservation
- QIB
- 21,000 shares (0.95% of the Offer)
- NII
- 10,89,000 shares (49.50% of the Offer)
- Retail
- 10,90,000 shares (49.55% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Skyline Financial Services- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 25 Mar 2026
- Refunds initiated
- 27 Mar 2026
- Shares credited to demat
- 27 Mar 2026
- Listing
- 30 Mar 2026
Grey market premium (GMP)
- Current GMP
- ₹0
- —
- Estimated listing price
- ₹124
- Issue price ₹124
- Highest
- ₹0
- 18 Mar
- Lowest
- ₹0
- 18 Mar
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 29 Mar 2026 | ₹0 | — | ₹124 |
| 28 Mar 2026 | ₹0 | — | ₹124 |
| 25 Mar 2026 | ₹0 | — | ₹124 |
| 24 Mar 2026 | ₹0 | — | ₹124 |
| 23 Mar 2026 | ₹0 | — | ₹124 |
| 21 Mar 2026 | ₹0 | — | ₹124 |
| 20 Mar 2026 | ₹0 | — | ₹124 |
| 19 Mar 2026 | ₹0 | — | ₹124 |
| 18 Mar 2026 | ₹0 | — | ₹124 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB96.24x
- NII (HNI)1.77x
- Retail0.85x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 21,000 | 20,21,000 | 96.24x |
| Non-Institutional Investors (NII) | 12,39,000 | 21,94,000 | 1.77x |
| Retail Individual Investors (RII) | 10,90,000 | 9,22,000 | 0.85x |
| Total | 23,50,000 | 51,37,000 | 2.19x |
Financials
- P/E Ratio
- 10.49
- EPS (₹)
- 11.82
- RoCE
- 33.39%
- RoNW
- 28.30%
- PAT Margin
- 14.77%
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Speciality Medicines This IPO | ₹29 Cr | 10.49 | 28.30% | 14.77% | 2.19x | 0.00% |
| Avience Biomedicals SME · listed 25 Jun 2026 | ₹30.24 Cr | 16.56 | 49.89% | 15.86% | 385.4x | +90.00% |
| Himalaya Nutravedics India SME · listed 29 Sep 2026 | ₹26.5 Cr | 12.63 | 45.12% | 17.16% | 2.24x | +11.32% |
| ABH Healthcare SME · listed 1 Sep 2026 | ₹34.98 Cr | 20.69 | 39.07% | 10.74% | 1.42x | -2.94% |
| Bio Medica Laboratories SME · listed 29 May 2026 | ₹52 Cr | 13.45 | 99.59% | 25.64% | 2.31x | -20.00% |
| Goldline Pharmaceutical SME · listed 19 May 2026 | ₹12 Cr | 13.93 | 27.37% | 10.09% | 781.85x | +38.95% |
| Pramodini Medicare SME · listed 19 Aug 2026 | ₹69.04 Cr | 14.97 | 32.69% | 27.90% | 3.66x | +1.69% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Speciality Medicines plans to use the money raised, as stated in the offer document.
- Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat₹12.68 Cr
- Product Registration in International Markets and Product Development for sale in international markets₹2.99 Cr
- Funding for Marketing and Promotional Activities₹1.66 Cr
- To Meet Working Capital Requirements₹8 Cr
- General Corporate Purposes
- Total₹25.33 Cr
About Speciality Medicines
Speciality Medicines Limited was established with the objective of catering to the growing demand for niche and high-value pharmaceutical products in India. Over the years, the company has built its presence in the healthcare sector by focusing on specialised therapeutic segments such as critical care, oncology, and chronic disease management. Promoted by experienced professionals from the pharmaceutical industry, the company has developed strong relationships with hospitals, healthcare institutions, and distributors across key regions. The company’s business model revolves around sourcing, marketing, and distribution of speciality drugs, along with a focus on quality and regulatory compliance. It offers a diverse portfolio of branded and generic medicines, targeting both domestic and selected international markets. By leveraging an asset-light approach and an efficient supply chain network, Speciality Medicines Limited aims to scale its operations while maintaining consistent product availability and expanding its reach in the healthcare ecosystem.
Promoters and shareholding
Parth B Goyani and Goyani Sumit Babubhai
- Promoter holding, pre-issue
- 59.28%
- Promoter holding, post-issue
- 43.44%
Registrar, lead managers and documents
Lead manager
Company contact
913, One World West, S.No.396, FP 119, Village-Vejalpur, Ahmadabad City, Ahmedabad, Gujarat, 380051
+91 22 4604 5344
investors.grievances@specialitymedicine.comSpeciality Medicines IPO: common questions
1.When does the Speciality Medicines IPO open and close?
The Speciality Medicines IPO opens on 20 Mar 2026 and closes on 24 Mar 2026.
2.What is the price band of the Speciality Medicines IPO?
The price band is ₹117 – ₹124 per share, with a lot size of 1,000 shares and a minimum investment of ₹1,24,000.
3.What is the size of the Speciality Medicines IPO?
The issue size is ₹29 Cr (NII Shares Offered).
4.What is the GMP of the Speciality Medicines IPO?
The last reported grey market premium is ₹0 per share as of 29 Mar 2026, 07:10 PM IST. GMP is unofficial and changes frequently.
5.When is the Speciality Medicines IPO allotment?
The basis of allotment is expected on 25 Mar 2026. Allotment status can be checked with the registrar, Skyline Financial Services Private Limited.
6.When will the Speciality Medicines IPO list?
The shares listed on 30 Mar 2026 on BSE SME.
7.Who is the lead manager of the Speciality Medicines IPO?
The book running lead manager is Unistone Capital, and the registrar is Skyline Financial Services Private Limited.
8.What will the money raised in the Speciality Medicines IPO be used for?
As stated in the offer document, the proceeds are for: Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat; Product Registration in International Markets and Product Development for sale in international markets; Funding for Marketing and Promotional Activities; To Meet Working Capital Requirements; General Corporate Purposes.
9.How can my company launch an IPO like Speciality Medicines?
Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393